



6th GUILDFORD ADVANCED PAIN & SYMPTOM MANAGEMENT COURSES

REFERENCE / READING LIST

Cognitive effects of opioids - safe to drive?

Dr Jason Boland

- Choi M, Lohman MC, Mezuk B. Trajectories of cognitive decline by driving mobility: evidence from the Health and Retirement Study. *Int J Geriatr Psychiatry* 2014; 29: 447-53.
- Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. *J Pain Symptom Manage* 2000; 19: 200-8.
- Helland A, Jenssen GD, Lervåg L-E et al. Evaluation of measures of impairment in real and simulated driving: results from a randomized, placebo-controlled study. *Traffic Inj Prev* 2016; 17: 245-50.
- Hetland A, Carr DB. Medications and impaired driving: a review of the literature. *Ann Pharmacother* 2014; 48: 494-506. [Available on Guildford Advanced Courses website]
- Mailis-Gagnon A, Lakha SF, Furlan A et al. Systematic review of the quality and generalizability of studies on the effects of opioids on driving and cognitive/psychomotor performance. *Clin J Pain* 2012; 28: 542-55.
- Menefee LA, Frank ED, Crerand C et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. *Pain Med* 2004; 5: 42-9.

- Mezuk B, Rebok GW. Social integration and social support among older adults following driving cessation. *J Gerontol B: Psychol Sci Soc Sci* 2008; 63: S298-S303.
- Nilsen HK, Landrø NI, Kaasa S et al. Driving functions in a video simulator in chronic non-malignant pain patients using and not using codeine. *Eur J Pain* 2011; 15: 409-15.
- Verster JC, Roth T. Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills. *Psychopharmacology* 2012; 220: 293-301.

Opioid overdose vs opioid toxicity

Dr Colette Reid

- Bohnert AS, Valentstein M, Bair MJ et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011; 305: 1315-21.
- Boland J, Boland E, Brooks D. Importance of the correct diagnosis of opioid-induced respiratory depression in adult cancer patients and titration of naloxone. *Clin Med (Lond)* 2013; 13: 149-51. [Available on Guildford Advanced Courses website]
- CNN website:
<http://edition.cnn.com/2017/06/23/health/opioid-overdose-library-narcan/index.html>
- Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. *Palliat Med* 2011; 25: 494-503.

- Gretton SK, Ross JR, Rutter D et al. Plasma morphine and metabolite concentrations are associated with clinical effects of morphine in cancer patients. *J Pain Symptom Manage* 2013; 45: 670-80.
- Hartung D, Middleton L, Haxby DG et al. Rates of adverse events of long-acting opioids in a state Medicaid program. *Ann Pharmacother* 2007; 41: 921-8.
- Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. *Crit Rev Oncol Hematol*. 2016; 99: 241-8.
- NHS England Patient Safety Alert:
<https://improvement.nhs.uk/uploads/documents/psa-naloxone-stage2.pdf>
- Pattinson K. Opioids and the control of respiration. *Br J Anaesth* 2008; 100: 747-58.
- Riley J, Branford R, Droney J et al. Morphine or oxycodone for cancer-related pain? A randomised, open-label, controlled trial. *J Pain Symptom Manage* 2015; 49: 161-72.

Tramadol / tapentadol

Dr Andrew Dickman

- Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. *Pain Med* 2015; 16: 119-30.
- Coluzzi F, Fornasari D, Pergolizzi J et al. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. *Eur Rev Med Pharmacol Sci* 2017; 21: 1672-83. [Available on Guildford Advanced Courses website]
- Langford RM, Knaggs R, Farquhar-Smith P et al. Is tapentadol different from classical opioids? A review of the evidence. *Br J Pain*. 2016; 10: 217-21.

- Lassen D, Damkier P, Brosen K. The pharmacogenetics of tramadol. *Clin Pharmacokinet* 2015; 54: 825-36.
- Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. *Pharmacol Rep* 2009; 61: 978-92. [Available on Guildford Advanced Courses website]
- Lopez Ramirez E, Munoz Carmona DM, Contreras Martinez J et al. Tapentadol in the management of opioid-naive patients with cancer pain. *Rev Soc Esp Dolor*. 2016; 23: 32-8.
- Raffa RB, Buschmann H, Christoph T et al. Mechanistic and functional differentiation of tapentadol and tramadol. *Expert Opin Pharmacother*. 2012; 13: 1437-49.

Pain in cancer survivors

Dr Kath Webber

- Glare PA, Davies PS, Finlay E et al. Pain in Cancer Survivors. *J Clin Oncol* 2014; 32: 1739-47.
- Paice JA, Portenoy R, Lacchetti C et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; 34: 3325-45.
- Richards M, Corner J, Maher J. The National Cancer Survivorship Initiative: new and emerging evidence on the ongoing needs of cancer survivors. *Br J Cancer* 2011; 105: S1-S4.

Ketamine

Dr Barry Laird

- Hardy J, Quinn S, Fazekas B et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. *J Clin Oncol* 2012; 30: 3611-7.
- Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. *Eur J Cancer* 2008; 44: 1078-82.
- Mulvey MR, Rolke R, Klepstad P et al. Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading system in clinical practice and clinical research. *Pain* 2014; 155: 859-63.
- Soto E. Relevance of ketamine in the management of cancer pain. *Ann Palliat Med* 2013; 2: 40-2.
- Zgaia AO, Irimie A, Sandesc D et al. The role of ketamine in the treatment of chronic cancer pain. *Clujul Med* 2015; 88: 457-61.

What else is new (pain)?

Dr Andrew Davies

- Aurora RN, Zak RS, Auerbach SH et al. Best practice guide for the treatment of nightmare disorder in adults. *J Clin Sleep Med* 2010; 6: 389-401. [Available on Guildford Advanced Courses website]
- Carr AC, McCall C. The role of vitamin C in the treatment of pain: new insights. *J Transl Med* 2017; 15: 77.

- Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency's "Suspected Adverse Drug Reactions" Database. *CNS Drugs* 2016; 30: 647-54.
- Davies AN, Patel SD, Gregory A et al. Observational study of sleep disturbance in advanced cancer. *BMJ Support Palliat Care* (in press).
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. *Drugs* 2017; 77: 403-26.
- Public Health England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. London: Public Health England and NHS England; 2014. [Available on Guildford Advanced Courses website]
- Lyndon A, Audrey S, Wells C et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. *Addiction* 2017; 112: 1580-9.
- Mayland CR, Bennett MI, Allan K. Vitamin C deficiency in cancer patients. *Palliat Med* 2006; 19: 17-20.
- Pinkerton E, Good P, Gibbons K et al. An open-label pilot study of oral vitamin C as an opioid-sparing agent in patients with chronic pain secondary to cancer. *Support Care Cancer* 2017; 25: 341-3.

Rationalising medications at the end of life

Ms Jo Thompson

- Chuang HY, Wen YW, Chen LK et al. Medication appropriateness for patients with dementia approaching the end of their life. *Geriatr Gerontol Int* 2017; 17 (Suppl1): 65-74.

- Dalleur O, Boland B, Losseau C et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. *Drugs Aging* 2014; 31, 291-8.
- Hochman MJ, Kamal AH, Wolf SP et al. Anticholinergic drug burden in non-cancer versus cancer patients near the end of life. *J Pain Symptom Manage* 2016; 52: 737-43.
- Holmes HM, Hayley DC, Alexander GC et al. Reconsidering medication appropriateness for patients late in life. *Arch Intern Med* 2006; 166: 605-9.
- Holmes HM, Sachs GA, Shega JW et al. Integrating palliative medicine into the care of persons with advanced dementia: Identifying appropriate medication use. *J Am Geriatr Soc* 2008; 56: 1306-11.
- Kutner JS, Blatchford PJ, Taylor DH Jr et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA Intern Med* 2015; 175: 691-700.
- LeBlanc Tw, McNeil MJ, Kamal AH et al. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. *Lancet Oncol* 2015; 16: e333-41.
- Lindsay J, Dooley M, Martin J et al. Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. *Support Care Cancer* 2014; 22: 1113-9.
- Lindsay J, Dooley M, Martin J et al. The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'. *Support Care Cancer* 2015; 23: 71-8.
- Maddison A, Fisher J, Johnston G. Preventive medication use among persons with limited life expectancy. *Prog Palliat Care* 2011; 19: 15-21. [Available on Guildford Advanced Courses web site]

- McNeil M, Kamal A, Kutner J et al. The burden of polypharmacy in patients near the end of life. *J Pain Symptom Manage* 2016; 51: 178-83.e2.
- Patterson SM, Cadogan CA, Kerse N et al. Interventions to improve the appropriate use of polypharmacy for older people. *Cochrane Database of Systematic Reviews* 2014, Issue 10. Art. No.: CD008165. [Available on Guildford Advanced Courses website]
- Pont L, Jansen K, Schaufel M et al. Drug utilisation and medication costs at the end of life. *Expert Rev Pharmacoecon Outcomes Res* 2016; 16: 237-43.
- Reeve E, Shakib S, Hendrix I et al. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. *Br J Clin Pharmacol* 2013; 78: 738-47. [Available on Guildford Advanced Courses website]
- Riechelmann RP, Zimmermann C, Chin SN et al. Potential drug interactions in cancer patients receiving supportive care exclusively. *J Pain Symptom Manage* 2008; 35: 535-43.
- Scott IA, Hilmer SN, Reeve E et al. Reducing inappropriate polypharmacy. The process of deprescribing. *JAMA Intern Med* 2015; 175: 827-34.
- Todd A, Holmes HM. Recommendations to support deprescribing medications late in life. *Int J Clin Pharm* 2015; 37: 678-81 [Available on Guildford Advanced Courses website]
- Van den Noortgate NJ, Verhofstede R, Cohen J et al. Prescription and deprescription of medication during the last 48 hours of life: multicenter study in 23 acute geriatric wards in Flanders, Belgium. *J Pain Symptom Manage* 2016; 51: 1020-26.

New drugs for anorexia / cachexia

Dr Andrew Dickman

- Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011; 12: 489-95.
- Bruggeman AR, Kamal AH, LeBlanc TW et al. Cancer cachexia: beyond weight loss. *J Oncol Pract.* 2016; 12: 1163-71.
- Von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. *J Am Med Dir Assoc* 2014; 15; 866-72. [Available on Guildford Advanced Courses website]
- Mattox TW. Cancer cachexia: cause, diagnosis, and treatment. *Nutr Clin Pract.* 2017 [Epub ahead of print].
- Currow D, Temel JS, Abernethy A et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. *Ann Oncol* 2017; 28: 1949-56. [Available on Guildford Advanced Courses website]

Opioid-induced constipation

Dr Andrew Davies

- Argoff CE, Brennan MJ, Camilleri M et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. *Pain Med* 2015; 16: 2324-37. [Available on Guildford Advanced Courses website]
- Camilleri M, Drossman DA, Becker G et al. Emerging Treatments in Neurogastroenterology: A Multidisciplinary Working Group Consensus Statement on

Opioid-Induced Constipation. *Neurogastroenterol Motil* 2014; 26: 1386-95. [Available on Guildford Advanced Courses website]

- Chey WD, Webster L, Sostek M et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. *N Engl J Med* 2014; 370: 2387-96. [Available on Guildford Advanced Courses website]
- Cryer B, Katz S, Vallejo R et al. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. *Pain Med* 2014; 15: 1825-34.
- Davies A, Webber K. Stercoral perforation of the colon: a potentially fatal complication of opioid-induced constipation. *J Pain Symptom Manage* 2015; 50: 260-2.
- Dhingra L, Shuk E, Grossman B et al. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. *Palliat Med* 2012; 27: 447-56.
- Hale M, Wild J, Reddy J et al. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, parallel group trials. *Lancet Gastroenterol Hepatol* 2017; 2: 555-64
- Jamal MM, Adams AB, Jansen J-P et al. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. *Am J Gastroenterol* 2015; 110: 725-32.
- Katakami N, Oda K, Tauchi K et al. Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. *J Clin Oncol*. 2017; 35: 1921-8.

- Sloots CE, Rykx A, Cools M et al. Efficacy and safety of prucalopride in patients with chronic non-cancer pain suffering from opioid-induced constipation. *Dig Dis Sci* 2010; 55: 2912-21.
- Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med* 2008; 358: 2332-43. [Available on Guildford Advanced Courses website]

Clinically-assisted nutrition in advanced cancer

Lindsey Allan

- Abbott J, Teleni L, McKavanagh D et al (2016) Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) is a valid screening tool in chemotherapy outpatients. *Supportive Care in Cancer* 24: 3883-7
- Andreyev HJ, Norman AR, Oates J, Cunningham D. (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *European Journal of Cancer* 34 (4): 503-509.
- Andreyev HJ, Muls AC, Norton C et al (2015) Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease. *Frontline Gastroenterology* 6:53-72
- Andreyev HJN et al (2016) Guide to managing persistent upper gastrointestinal symptoms during and after treatment for cancer *Frontline Gastroenterology* 0:1-29. Doi:10.1136/flgastro-2016-100714
- Arends J, Bachmann P, Baracos V et al (2016) ESPEN Guidelines on nutrition in cancer patients. *Clinical Nutrition* pii: S0261-5614(16)30181-9. doi: 10.1016/j.clnu.2016.07.015. [Epub ahead of print]

- Arrieta O, De La Torre-Vallejo M et al. (2015) Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. *Oncologist* 20(8): 967–974
- Baldwin C, Spiro A, Ahern R, Emery PW. (2012) Oral Nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. *J Natl Cancer Inst* 104: 371-385
- Bosaeus J, Daneryd P, Svanberg E, Lundholm K. (2001) Dietary intake, resting energy expenditure in relation to weight loss in unselected cancer patients. *Int J Cancer* 93:380-3
- Bozzetti F (2010). Nutritional support in patients with oesophageal cancer. *Supportive Care in Cancer* 18 S2:S41-50.
- Cano NJM, Aparicio M, Brunori G et al. (2009) ESPEN Guidelines for adult parenteral nutrition. *Clinical Nutrition* 29: 359-479.
- DeWys WD et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *American Journal of Medicine* 69 (4) 491-497.
- Druml C, Ballmer PE et al (2016) ESPEN guideline on ethical aspects of artificial nutrition and hydration. *Clinical Nutrition* 35: 545-556
- Fan BG (2007). Parenteral nutrition prolongs the survival of patients associated with malignant gastrointestinal obstruction. *JPEN* 31(6):508-510.
- Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. *Lancet* 12(5): 489-95.

- Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, von Meyenfeldt MF, Saris WH. (1991) Effect of different tumor types on resting energy expenditure. *Cancer Res* 51: 6138-6141.
- Hug A, Phillips I, Allan L, Ezhil V (2016) Rate of cachexia in lung cancer. *Eur J Surg Oncol* 42(11): S227
- Klute KA, Brouwer J, Jhaver M et al. (2016) Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. *European Journal of Cancer* 63:189-200
- Löser C, Aschl G, Hébuterne X et al. (2005) ESPEN Guidelines on enteral nutrition - Percutaneous endoscopic gastrostomy (PEG). *Clinical Nutrition* 24: 848-861.
- NICE (2012). Nutrition Support in Adults, a quality Standard. Accessed online 23/10/2016
<https://www.nice.org.uk/guidance/qs24/resources/nutrition-support-in-adults-2098545777349>
- Naghibi M, Smith TR, Elia M. (2015) A systematic review with meta-analysis of survival, quality of life and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. *Clinical Nutrition* 34(5):825-37
- Norman, C Pichard, H Lochs, M Pirlich. Prognostic impact of disease-related malnutrition. *Clin Nutr.* 2008;27:5–15, 101016/j.clnu.2007.10.007.
- Odelli C, Burgess D, Bateman L et al. (2005) Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. *Clin Oncol (R Coll Radiol)* 18(8): 639-45

- Paccagnella A, Morello M, Da Mosto MC et al. (2010) Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. *Support Care Cancer* 18(7): 837-45
- Pamoukdjan F, Bouillet T, Levy V et al (2017) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. *Clin Nutr* S0261-5614(17)30249-2. doi: 10.1016/j.clnu.2017.07.010. [Epub ahead of print]
- Poulsen GM, Pedersen LL, Østerlind K et al (2014) Randomized trial of the effects of individual nutritional counseling in cancer patients. *Clin Nutr* 33(5):749-53.
- Sánchez-Lara K, Turcott JG, Juárez-Hernández E et al. (2014) Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. *Clin Nutr* 33(6): 1017-23
- Stratton RJ, Green CJ, Elia M (2003). *Disease-related Malnutrition: an Evidenced-Based Approach to Treatment*. CABI Publishing, Walingford.
- Uster A, Ruehlin M, Mey S (2017) Effects of nutrition and physical exercise intervention in palliative cancer patients: A randomized controlled trial. *Clin Nutr* S0261-5614(17)30201-7. doi: 10.1016/j.clnu.2017.05.027. [Epub ahead of print]
- Uster A, Ruefenacht U, Ruehlin M et al. (2013) Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: A randomized controlled trial. *Nutrition* 29: 1342-1349.
- Wedlake L, Shaw C, McNair H et al (2017) Randomised controlled trial of dietary fibre for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. *Am J Clin Nutr* 106: 849-857

- Weekes CE, Elia M, Emery PW (2004) The development, validation and reliability of a nutrition screening tool based on the recommendations of the British Association for Parenteral and Enteral Nutrition (BAPEN). *Clin Nutr* 23(5):1104-1112.
- Yavuzsen T, Davis MP, Walsh D et al (2005) Systematic review of the treatment of cancer-associated anorexia and weight loss. *J Clin Oncol.* 23(33):8500-11

Sexual problems

Dr Bridget Taylor

- Foley S, Kope S, Sugrue D (2011) *Sex Matters for Women: A Complete Guide to Taking Care of Your Sexual Self* (2nd edition). London: The Guildford Press.
- Kaufman M, Silverberg C, Odette F (2007) *The Ultimate Guide to Sex and Disability*. San Francisco: Cleis Press Inc.
- Lemieux L, Kaiser S, Pereira J, Meadows L (2004) Sexuality in palliative care: patient perspectives. *Palliative Medicine* 18(7) 630-637.
- Marie Curie (2016) *Hiding who I am*
<https://www.mariecurie.org.uk/globalassets/media/documents/policy/policy-publications/june-2016/reality-end-of-life-care-lgbt-people.pdf>
- Marsden R, Taylor B (2016) *Leaflet 13A: Sex and Relationships: for People Living with MND*. Northampton: Motor Neurone Disease Association. Available from:
<http://www.mndassociation.org/wp-content/uploads/13A-Sex-and-relationships-pwMND.pdf?1bcb49>
- Marsden R, Taylor B (2016) *Leaflet 13B: Sex and Relationships: for Partners of People Living with MND*. Northampton: Motor Neurone Disease Association. Available from:

<http://www.mndassociation.org/wp-content/uploads/2015/06/13b-sex-and-relationships-partners.pdf?1bcb49>

- Royal College of Nursing (2011) *Older People in Care Homes: Sexuality and Intimate Relationships*. London: Royal College of Nursing.
- Taylor B (2015) Does the caring role preclude sexuality and intimacy in coupled relationships? *Sexuality & Disability*, 33(3), 365-374.
- Taylor B (2014) Experiences of sexuality and intimacy in terminal illness: A phenomenological study. *Palliative Medicine*, 28(5), 438-447.
- Taylor B (2011) The impact of assistive equipment on intimacy and sexual expression. *British Journal of Occupational Therapy* 74(9) 435-442.
- Taylor B, Davis S (2007) The extended PLISSIT Model for addressing the sexual wellbeing of individuals with an acquired disability or chronic illness. *Sexuality and Disability* 25(3) 135-139. View on-line at: <http://rdcu.be/mU7C>
- University of Nottingham (2015) *The Last Outing*. Nottingham: University of Nottingham.
<https://www.nottingham.ac.uk/research/groups/srcc/documents/projects/srcc-project-report-last-outing.pdf>

Useful organisations

- College of Sexual and Relationship Therapists (COSRT)

Provides information on sexual problems and a list of local therapists.

Telephone: 020 8543 2707

Email: info@cosrt.org.uk

Website: www.cosrt.org.uk

- LGBT Foundation

Provides information, support and advice to lesbian, gay and bisexual people. They offer online support and a forum specifically for carers.

Telephone: 0345 330 3030

Email: info@lgbt.foundation

Website: <http://lgbt.foundation>

- NAPAC

Provides support for adult survivors of childhood abuse, and those who support them.

Telephone: 0808 801 0331 [10am-9pm Mon-Thurs; 10am -6pm Fri]

Website: <http://napac.org.uk>

- Outsiders

An organisation for people with physical and/or social disabilities. Their helpline provides guidance on sex and relationship problems, and they have a number of social groups.

Telephone: 0707 499 3527 (Sex and Disability Helpline)

Email: info@outsiders.org.uk

sexdis@outsiders.org.uk (sexual information and advice)

Website: www.outsiders.org.uk

- Relate

Provides information, counselling or psychosexual therapy for relationship concerns.

Telephone: 0300 100 1234

Email: Via the website

Website: www.relate.org.uk

- The Sexual Advice Association

Provides information and advice about a range of sexual issues.

Telephone: 020 7486 7262 (helpline)

Email: info@sexualadviceassociation.co.uk

Website: www.sexualadviceassociation.co.uk

- SH&DA Sexual Health and Disability Alliance

For health and social care professionals supporting disabled people with sex and relationship needs.

Telephone: 0707 499 3527

Email: Trust@Outsiders.org.uk

Website: www.shada.org.uk

Palliative care for teenagers and young adults

AK Anderson

- Anghelescu D, Patel RM, Mahoney DP et al. Methadone prolongs cardiac conduction in young patients with cancer-related pain. *J Opioid Manag* 2016; 12: 131-8.
- Anghelescu DL, Zhang K, Faughnan LG et al. The safety and effectiveness of patient-controlled analgesia in outpatient children and young adults with cancer: a retrospective study. *J Pediatr Hematol Oncol* 2015; 37: 378-82.
- Bell CJ, Zimet GD, Hinds PS et al. Refinement of a conceptual model for adolescent readiness to engage in end-of-life discussions. *Cancer Nurs* 2017 [Epub ahead of print].
- Bredlau AL, Thakur R, Korones D et al. Ketamine for pain in adults and children with

cancer: a systematic review and synthesis of the literature. *Pain Med* 2013; 14: 1505-17.

- Du Plessis K, Culnane E, Peters R et al. Adolescent and parent perspectives prior to involvement in a Fontan transition program. *Int J Adolesc Med Health* 2017 [Epub ahead of print].
- Fraser LK, Miller M, Hain R et al. Rising national prevalence of life-limiting conditions in children in England. *Pediatrics* 2012; 129: e923-9.
- Håkanson C, Öhlén J, Kreicbergs U et al. Place of death of children with complex chronic conditions: cross-national study of 11 countries. *Eur J Pediatr*; 2017; 176: 327-35.
- Hølge-Hazelton B, Timm HU, Graugaard C et al. "Perhaps I will die young." Fears and worries regarding disease and death among Danish adolescents and young adults with cancer. A mixed method study. *Support Care Cancer* 2016; 24: 4727-37.
- Horridge KA. Advance Care Planning: practicalities, legalities, complexities and controversies. *Arch Dis Child* 2015; 100: 380-5.
- Hughes RE, Holland LR, Zanino D et al. Prevalence and intensity of pain and other physical and psychological symptoms in adolescents and young adults diagnosed with cancer on referral to a palliative care service. *J Adolesc Young Adult Oncol* 2015; 4: 70-5.
- Jalmsell L, Lövgren M, Kreicbergs U et al. Children with cancer share their views: tell the truth but leave room for hope. *Acta Paediatr* 2016; 105: 1094-9
- Kaal SE, Kuijken NM, Verhagen CA et al. Experiences of parents and general practitioners with end-of-life care in adolescents and young adults with cancer. *J Adolesc Young Adult Oncol* 2016; 5: 64-8.

- Kamperidis N, Goodhand JR, Chowdhury FA et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2012; 54: 685-9.
- Keim-Malpass J, Stegenga K, Loudin B et al. "It's back! My remission is over": online communication of disease progression among adolescents with cancer. *J Pediatr Oncol Nurs* 2016; 33: 209-17.
- Kondryn HJ, Edmondson CL, Hill J et al. Treatment non-adherence to teenage and young patients with cancer. *Lancet Oncol* 2011; 12: 100-8.
- Landier W. Adherence to oral chemotherapy in childhood acute lymphoblastic leukaemia : an evolutionary concept analysis. *Oncol Nurs Forum* 2011; 38: 343-52.
- Nayak S, Cunliffe M. Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: report of five cases. *Paediatr Anaesth* 2008; 18: 554-8.
- Othman AH, Mohamad MF, Sayed HA. Transdermal fentanyl for cancer pain management in opioid-naïve pediatric cancer patients. *Pain Med* 2016 [Epub ahead of print].
- Poort H, Kaal SE, Knoop H et al. Prevalence and impact of severe fatigue in adolescent and young adult cancer patients in comparison with population-based controls. *Support Care Cancer* 2017; 25: 2911-8.
- Rosenberg AR, Wolfe J, Wiener L et al. Ethics, emotions, and the skills of talking about progressing disease with terminally ill adolescents: a review. *JAMA Pediatr* 2016; 170: 1216-23.
- Snaman JM, Kaye EC, Lu JJ et al. Palliative care involvement is associated with less intensive end-of-life care in adolescent and young adult oncology patients. *J Palliat Med* 2017; 20: 509-16.

- Somanadhan S, Larkin PJ. Parents' experiences of living with, and caring for children, adolescents and young adults with mucopolysaccharidosis (MPS). *Orphanet J Rare Dis* 2016; 11: 138.
- Steele R, Siden H, Cadell S et al. Charting the territory: symptoms and functional assessment in children with progressive, non-curable conditions. *Arch Dis Child*. 2014; 99: 754-62.
- Valrie C, Bromberg M, Palermo T et al. A systematic review of sleep in pediatric pain populations. *J Dev Behav Pediatr* 2013; 34: 120-8.
- Vondracek P, Oslejskova H, Kepak T et al. Efficacy of pregablin in neuropathic pain in paediatric oncological patients. *Eur J Paediatr Neurol* 2009; 13: 332-6.